Pharmaceutical Investing La Jolla Pharmaceutical Company Gets European Commission Approval for GIAPREZA
Pharmaceutical Investing La Jolla Pharmaceutical Company Receives Orphan Designation from FDA for LJPC-0118
Pharmaceutical Investing La Jolla Pharmaceutical Company Announces U.S. FDA’s Grant of Breakthrough Therapy Designation for LJPC-0118
Pharmaceutical Investing La Jolla Pharmaceutical Company Announces European Medicines Agency Validation of Marketing Authorisation Application for GIAPREZA
Noble Mineral highlights Successful Exploration Results announced by Canada Nickel, including Highest Grade to Date at Mann West
